Trilostane

Drug Profile

Trilostane

Alternative Names: Abetafen; Modrastane; Modrefen; Modrenal

Latest Information Update: 14 Dec 2016

Price : $50

At a glance

  • Originator Stegram Pharmaceuticals
  • Class Androstanols; Testosterone congeners
  • Mechanism of Action 3-hydroxysteroid dehydrogenase inhibitors; Estrogen receptor antagonists; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • No development reported Adrenal cortical hyperfunction; Prostate cancer
  • Discontinued Alzheimer's disease

Most Recent Events

  • 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
  • 08 Sep 2009 No development reported - Clinical for Breast cancer in European Union (PO)
  • 08 Sep 2009 No development reported - Clinical-Phase-Unknown for Breast cancer in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top